Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9Y2R4
UPID:
DDX52_HUMAN
Alternative names:
ATP-dependent RNA helicase ROK1-like; DEAD box protein 52
Alternative UPACC:
Q9Y2R4; Q86YG1; Q8N213; Q9NVE0; Q9Y482
Background:
The Probable ATP-dependent RNA helicase DDX52, also known as ATP-dependent RNA helicase ROK1-like and DEAD box protein 52, plays a crucial role in ribosome biogenesis, akin to its counterparts. It is speculated to regulate cell cycle progression by modulating the translation of mRNAs with a terminal oligo pyrimidine (TOP) motif in their 5' UTRs, including GTPBP4.
Therapeutic significance:
Understanding the role of Probable ATP-dependent RNA helicase DDX52 could open doors to potential therapeutic strategies, especially in the realm of diseases where ribosome biogenesis and cell cycle regulation are compromised.